New Guidelines Personalize Cholesterol Treatment

Updated dyslipidemia guidance arrived in March 2026, replacing recommendations last revised in 2018. The American Heart Association issued it with the American College of Cardiology. The update favors earlier, more intensive control because longer exposure to elevated cholesterol is strongly associated with greater lifetime cardiovascular risk. This matters widely: dyslipidemia affects at least one-fourth of Americans, and poorly controlled cholesterol can contribute to artery-clogging plaque linked with stroke and heart attack.

Treatment decisions now draw on a broader picture of personal risk. Alongside LDL, HDL, triglycerides and total cholesterol, clinicians can consider ApoB and LpA. ApoB counts plaque-forming particles and may be especially informative for people with diabetes, metabolic syndrome, normal LDL or elevated triglycerides. LpA resembles LDL but has an added protein that makes it more likely to promote arterial plaque. Every adult should have LpA measured once, according to the guidance. A coronary artery calcium score from a CT scan can further refine risk by showing calcium deposits near the heart.

The PREVENT-ASCVD calculator sorts patients into low, intermediate or high risk using factors such as body mass index, blood pressure, smoking status, kidney function and diabetes history. Beginning at age 30, it estimates cardiovascular risk across both 10-year and 30-year periods. Statins, including atorvastatin (Lipitor) and rosuvastatin (Crestor), remain standard treatment. Other medication classes may be added when statins do not meet cholesterol targets or cause intolerable side effects. Screening is also moving earlier: children ages 9 to 11 should be tested, while adults should begin at 19 and repeat testing every five years. Those with higher cardiovascular risk may consider medication from age 30.